Emerging drugs for diffuse large B-cell lymphoma Journal Article
| Authors: | Mondello, P.; Younes, A. |
| Article Title: | Emerging drugs for diffuse large B-cell lymphoma |
| Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma in western countries. Despite the addition of rituximab to chemotherapy, the prognosis is still poor and almost one-third of patients fail or relapse after first-line treatment. Gene expression profiling has identified three main signatures related to subgroups with different biological characteristics and responses to treatment. Novel agents targeting the oncogenic drivers of these subsets are currently under investigation with the aim of providing a tailored approach and avoiding unnecessary toxicity. Herein, we review the emerging therapies for DLBCL with a focus on preclinical and early clinical trials as well as future directions. © 2015 Informa UK Ltd. |
| Keywords: | signal transduction; treatment response; overall survival; fludarabine; lenalidomide; neutropenia; review; cisplatin; doxorubicin; hypertension; monotherapy; nonhuman; unspecified side effect; cytarabine; rituximab; carboplatin; unindexed drug; cancer immunotherapy; progression free survival; anemia; bone marrow suppression; protein targeting; etoposide; thrombocytopenia; peripheral neuropathy; cyclophosphamide; dexamethasone; vincristine; creatinine blood level; antineoplastic activity; phosphatidylinositol 3 kinase; ifosfamide; monoclonal antibodies; hyperglycemia; drug fatality; prednisolone; mammalian target of rapamycin; large cell lymphoma; everolimus; eye toxicity; lymphocyte antigen receptor; pi3k; blurred vision; myc; protein synthesis inhibition; programmed death 1 receptor; dlbcl; bcl-2; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); ofatumumab; bromodomain; hdac; blinatumomab; idelalisib; nivolumab; ibrutinib; pidilizumab; human; copanlisib; coltuximab ravtansine; duvelisib; obinutuzumab; pinatuzumab vedotin; polatuzumab vedotin |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 15 |
| Issue: | 4 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2015-04-01 |
| Start Page: | 439 |
| End Page: | 451 |
| Language: | English |
| DOI: | 10.1586/14737140.2015.1009042 |
| PROVIDER: | scopus |
| PUBMED: | 25652253 |
| DOI/URL: | |
| Notes: | Export Date: 4 May 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work